Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Income (2016 - 2025)

Historic Net Income for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to -$90.8 million.

  • Viking Therapeutics' Net Income fell 26279.32% to -$90.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$237.3 million, marking a year-over-year decrease of 13932.5%. This contributed to the annual value of -$110.0 million for FY2024, which is 2817.25% down from last year.
  • According to the latest figures from Q3 2025, Viking Therapeutics' Net Income is -$90.8 million, which was down 26279.32% from -$65.5 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Net Income high stood at -$12.4 million for Q4 2021, and its period low was -$90.8 million during Q3 2025.
  • In the last 5 years, Viking Therapeutics' Net Income had a median value of -$19.6 million in 2022 and averaged -$27.4 million.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 1044.42% in 2023, then crashed by 26279.32% in 2025.
  • Viking Therapeutics' Net Income (Quarter) stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then crashed by 44.0% to -$35.4 million in 2024, then plummeted by 156.51% to -$90.8 million in 2025.
  • Its last three reported values are -$90.8 million in Q3 2025, -$65.5 million for Q2 2025, and -$45.6 million during Q1 2025.